Class summary at a glance.

Every drug in the CD38-directed Cytolytic Antibody class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $29.3Mcombined across class
Total Rx claims: 3K373 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Daratumumab

Brand: DARZALEX · 3K Part D claims (CY24) · 373 beneficiaries · First FDA approval: 2015-11-16

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $29.3M

Class share

100%

of class CY24 spend

View profile →

Daratumumab and Hyaluronidase-Fihj (Human Recombinant)

Brand: Darzalex Faspro · — Part D claims (CY24) · First FDA approval: 2020-05-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Isatuximab

Brand: Sarclisa · — Part D claims (CY24) · First FDA approval: 2020-03-02

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.